Please login to the form below
linagliptin
This page shows the latest linagliptin news and features for those working in and with pharma, biotech and healthcare.
Boehringer bolsters NASH pipeline with $870m Yuhan deal
Boehringer already has an existing relationship with Yuhan, which acts as the South Korean marketer for three of the German firm’s Eli Lilly-partnered diabetes therapies, Tradjenta (linagliptin), Trajenta Duo ... linagliptin/metformin) and Jardiance
Latest news
-
Lilly claims cluster headache first for CGRP drug Emgality
Tradjenta (linagliptin) and metformin – and said yesterday the FDA had started its review of the Boehringer Ingelheim-partnered drug.
-
Boehringer Ingelheim calls for "strong and united" Europe
In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of lung disease therapy Ofev (nintedanib) more than doubled to
-
AZ gets US approval for diabetes combo Qtern
It is the second combination of its type to be approved for marketing in the US after Eli Lilly and Boehringer Ingelheim's Glyxambi (linagliptin/empagliflozin).
-
EU clears AZ's FDA-rejected diabetes combination
Eli Lilly and Boehringer Ingelheim's Glyxambi (linagliptin/empagliflozin).
-
Boehringer Ingelheim returns to growth after US turnaround
Sales of DPP-4 inhibitor Trajenta (linagliptin) and its Jentadueto (linagliptin and metformin) combination rose 42.9% to 909m.
More from news
Approximately 3 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
Notable points are that despite the considerable promotion and, some would say, superior clinical data, none of the SGLT2s has exceeded Trajenta (linagliptin) - a 4th entrant DPP4 in sales.
-
Interview: Beate Wieseler, IQWIG
This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).
-
A new dogma in HTA assessment
The G-BA had specified that linagliptin should be compared with a drug from the sulphonylurea class, such as glibenclamide or glimepiride. ... However, IQWiG was unable to infer any such benefit from the dossier because the manufacturers compared
-
Country report: The healthcare market in Germany
Out of the 10 products assessed last year, four have obtained poor innovation scores: Esbriet (pirfenidone), Livazo (pitavastatin), Yellox (bromfenac) and Trajenta (linagliptin) and a majority of manufacturers have struggled – sometimes
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU outlines measures to mitigate antibiotic shortage across Europe
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Merging global and local pharmacovigilance operations into a successful integrated approach
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
